[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610352":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":36,"centralContacts":40,"locations":45,"responsibleParty":62,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":10,"overallStatus":82,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adults with Brain Tumor Receiving Radiotherapy",null,"The study entails longitudinal assessment of plasma biomarkers (Aβ, GFAP, phospho Tau, NfL), determination of APOE genotype, neuropsychiatric testing Brain Health Assessment test (BHA), a clinically validated neurocognitive battery compiling metrics on memory and language), and brain morphometric measurements synchronized with standard of care brain MRIs.",[13,14,15,16],"Procedure: Blood sample","Procedure: Brain magnetic resonance imaging (MRI)","Procedure: Brain Health Assessment","Radiation: Quality of Life (QoL) Questionnaire",[18,23,27,31],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"PROCEDURE","Blood sample","Blood sample will be collected",[9],{"type":19,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Brain magnetic resonance imaging (MRI)","Brain MRI will be performed during the course of data collection",[9],{"type":19,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Brain Health Assessment","Brain Health Assessment will be performed during the course of data collection",[9],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":10},"RADIATION","Quality of Life (QoL) Questionnaire","QoL questionnaire will be given to participants during the course of data collection",[9],[37],{"name":38,"affiliation":5,"role":39},"Jean Nakamura, MD","PRINCIPAL_INVESTIGATOR",[41],{"name":38,"role":42,"phone":43,"phoneExt":10,"email":44},"CONTACT","(415) 514-4997","Jean.Nakamura@ucsf.edu",[46],{"facility":5,"status":10,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"San Francisco","California","94143","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-122.41942,37.77493,{"lat":56,"lon":55},[59],{"name":38,"role":42,"phone":60,"phoneExt":10,"email":61},"877-827-3222","cancertrials@ucsf.edu",{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100610352","evaluating-biomarkers-of-cognitive-dysfunction-in-patients-with-cancer-100610352",false,"NCT07226466","Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer","Inclusion Criteria:\n\n1. \\>= 18 years old\n2. Diagnosis of a primary brain tumor OR #3. Not both #2 and #3.\n3. Diagnosis of primary solid tumor and secondary involvement of the brain\n4. If the patient has brain metastases: fewer than 5 brain metastases (post-operative and definitive allowed), none \\> 1 cm in max diameter.\n5. Candidate for standard of care \u002F usual care (SOC) focused brain radiotherapy.\n6. No prior brain radiotherapy, including whole brain radiotherapy.\n7. Eastern Cooperative Oncology Group (ECOG) functional score 0 or 1.\n8. Estimated life expectancy post-treatment of \\> 2 years.\n\nExclusion Criteria:\n\n1. Diagnosis of neurodegenerative disease (Alzheimer's disease, Parkinson's disease).\n2. Diagnosis of memory disorder pre-treatment.\n3. Leptomeningeal disease or disease involving either hippocampus.","ALL","18 Years",{"count":73,"type":74},40,"ESTIMATED","OBSERVATIONAL","This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.",[78,79,80,81],"Brain Tumor Adult","Brain Metastases From Solid Tumors","Brain Tumor, Primary","Brain Tumor","NOT_YET_RECRUITING","2026-05-20",{"date":85,"type":86},"2026-05-22","ACTUAL",{"date":88,"type":74},"2026-07-01",{"date":90,"type":74},"2028-10-31",{"name":5,"class":6},1]